---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-080509"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T10:02:11.798729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Incannex reports positive Phase 2 results for PSX-001 in Generalized Anxiety Disorder

## Summary
- Psi-GAD (PSX-001) achieved a 12.8-point HAM-A reduction vs. 3.6 for placebo (p<0.0001) over 11 weeks.
- 44.1% of patients had clinical response (≥50% HAM-A reduction) and 27% achieved full remission (HAM-A ≤7).
- GAD-7 scores fell 7.4 points, SDS improved 6.0 points, PHQ-9 dropped 3.9 points, all statistically significant.
- No serious adverse events reported; only one subject withdrew from the 73-participant trial.
- Incannex plans a multi-jurisdiction Phase 2 trial and is exploring strategic partnerships for PSX-001.

## SEC filing metadata
- accession: 0001213900-25-080509
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025080509/0001213900-25-080509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025080509/ea0254452-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-080509
- JSON: https://secwatch.observer/filing/0001213900-25-080509.json
- Plain text: https://secwatch.observer/filing/0001213900-25-080509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.